CircuLex High-Sensitivity CRP ELISA Kit

  • Applications
    • ELISA
  • Code # CY-8071
  • Size 96 Assays
  • Price
    $513.71
Specifications

Background

C-Reactive protein (CRP) is a pentameric acute phase reactant that is synthesized by the liver. Its production is controlled primarily by interleukin-6. The serum CRP concentration may increase by up to 1000-fold with infection, ischemia, trauma, surgery, and other acute inflammatory events (1). Thus CRP can be used as an extremely sensitive systemic marker of inflammation. Especially in situations where microbiological diagnosis is difficult or too slow in the clinical context, CRP measurements can be used to infer the presence of bacterial infection (2). Ligand-bound or aggregated CRP binds C1q which then activates the classical complement pathway (3). Although primarily synthesized in hepatocytes, there is evidence for local expression of CRP in macrophages of the lung and the brain (4–6). In atherosclerotic plaques, it has been found to be associated with complement proteins and within foam cells (7, 8). A growing number of studies suggest that CRP is an independent risk factor for atherosclerotic vascular disease. Plasma CRP concentrations in the highest quartile are associated, depending on the subject group, with 1.5- to 7-fold increases in relative risk of symptomatic atherosclerosis (1, 9) The baseline plasma concentration of C-reactive protein predicts the risk of future myocardial infarction and stroke (10) and is associated with a poor prognosis in unstable angina (11–13). Plasma CRP levels are also strongly associated with obesity and obesity-related diseases, including insulin resistance, diabetes mellitus, and hyperlipidemia (14–17). Although a recent report indicated that the plasma CRP level decreased during weight reduction (17), the precise interaction of CRP with obesity has not been fully elucidated.
  • Application:
    ELISA
  • Components:
    • Microplate
    • 10X Wash Buffer
    • Dilution Buffer
    • Human CRP Standard
    • HRP conjugated Detection Antibody
    • Substrate Reagent
    • Stop Solution
  • Description:

    The CircuLex High-Sensitivity CRP ELISA Kit is used for the quantitative measurement of Human C-reactive protein (CRP) in serum, plasma and other biological media. It can be used for 96 Assays.

  • Product Type:
    ELISA Kit
  • Research Area:
    Metabolism
  • Short Description:

    CircuLex High-Sensitivity CRP ELISA Kit.

  • Size:
    96 Assays
Citations
  1. Ortega E et al. Aquatic exercise improves the monocyte pro- and anti-inflammatory cytokine production balance in fibromyalgia patients. Scand J Med Sci Sports. 22, 104-12 (2012)
  2. Pascale S et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 119, 3595-603 (2012),
  3. Hiura K et al. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis. Rheumatol Int. 33, 2309-14 (2013),
  4. Umeno A et al. Singlet oxygen induced products of linoleates, 10- and 12-(Z,E)-hydroxyoctadecadienoic acids (HODE), can be potential biomarkers for early detection of type 2 diabetes. PLoS One. 8, e63542 (2013)
  5. Yamaguchi Y et al. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res. 132, 263-70 (2013)
  6. Nakamura T et al. Role of high-sensitivity C-reactive protein in the differentiation of benign and malignant soft tissue tumors. Anticancer Res. 34, 933-6 (2014),
  7. Shindo A et al. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. PLoS One. 9, e100045 (2014),
  8. Yilmaz Ö et al. The effect of prolactin levels on MPV in women with PCOS. Clin Endocrinol. 82, 747-52 (2015)
  9. Fuchiwaki Y et al. New approach to a practical quartz crystal microbalance sensor utilizing an inkjet printing system. Sensors. 14, 20468-79 (2014)
  10. Yilmaz & Ouml; et al. Association between red blood cell distribution width and polycystic ovary syndrome. Endocr Res. 1-7 (2014)
References
  1. Westhuyzen J, Healy H. Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci. 2000; 30: 133–143.
  2. Makayama, T. et al. (1993) Clinical Chemistry. 39(2): 293-297.
  3. Du Clos TW. Function of C-reactive protein. Ann Med. 2000; 32: 274–278.
  4. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol. 1996; 156: 4815–4820.
  5. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 2001; 69: 1747–1754.
  6. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039–1051.
  7. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20: 2094–2099.
  8. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 2000; 10: 435–451.
  9. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J. 1996; 312: 1061–1065.
  10. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–979.
  11. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J. 2000; 140: 324–328.
  12. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol. 2000; 35: 1535–1542.
  13. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331: 417–424.
  14. Festa A, D’Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102: 42–47.
  15. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282: 2131–2135.
  16. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327–334.
  17. Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002; 105: 564–569.